Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis.
[gm1 gangliosidosis]
Gangliosides
are
the
main
glycolipids
of
neuronal
plasma
membranes
.
Their
surface
patterns
are
generated
by
coordinated
processes
,
involving
biosynthetic
pathways
of
the
secretory
compartments
,
catabolic
steps
of
the
endolysosomal
system
,
and
intracellular
trafficking
.
Inherited
defects
in
ganglioside
biosynthesis
causing
fatal
neurodegenerative
diseases
have
been
described
so
far
almost
exclusively
in
mouse
models
,
whereas
inherited
defects
in
ganglioside
catabolism
causing
various
clinical
forms
of
GM
1
-
and
GM
2
-
gangliosidoses
have
long
been
known
.
For
digestion
,
gangliosides
are
endocytosed
and
reach
intra-endosomal
vesicles
.
At
the
level
of
late
endosomes
,
they
are
depleted
of
membrane-stabilizing
lipids
like
cholesterol
and
enriched
with
bis
(
monoacylglycero
)
phosphate
(
BMP
)
.
Lysosomal
catabolism
is
catalyzed
at
acidic
pH
values
by
cationic
sphingolipid
activator
proteins
(
SAPs
)
,
presenting
lipids
to
their
respective
hydrolases
,
electrostatically
attracted
to
the
negatively
charged
surface
of
the
luminal
BMP-rich
vesicles
.
Various
inherited
defects
of
ganglioside
hydrolases
,
e
.
g
.
,
of
β-galactosidase
and
β-hexosaminidases
,
and
of
GM
2
-
activator
protein
,
cause
infantile
(
with
tetraparesis
,
dementia
,
blindness
)
and
different
protracted
clinical
forms
of
GM
1
-
and
GM
2
-
gangliosidoses
.
Mutations
yielding
proteins
with
small
residual
catabolic
activities
in
the
lysosome
give
rise
to
juvenile
and
adult
clinical
forms
with
a
wide
range
of
clinical
symptomatology
.
Apart
from
patients
'
differences
in
their
genetic
background
,
clinical
heterogeneity
may
be
caused
by
rather
diverse
substrate
specificities
and
functions
of
lysosomal
hydrolases
,
multifunctional
properties
of
SAPs
,
and
the
strong
regulation
of
ganglioside
catabolism
by
membrane
lipids
.
Currently
,
there
is
no
treatment
available
for
neuronal
ganglioside
storage
diseases
.
Therapeutic
approaches
in
mouse
models
and
patients
with
juvenile
forms
of
gangliosidoses
are
discussed
.
Diseases
Validation
Diseases presenting
"wide range"
symptom
22q11.2 deletion syndrome
acute rheumatic fever
adrenomyeloneuropathy
alexander disease
allergic bronchopulmonary aspergillosis
alpha-thalassemia
aromatase deficiency
benign recurrent intrahepatic cholestasis
cadasil
carcinoma of the gallbladder
congenital toxoplasmosis
cowden syndrome
cystinuria
dystrophic epidermolysis bullosa
epidermolysis bullosa simplex
erdheim-chester disease
fabry disease
gm1 gangliosidosis
harlequin ichthyosis
homocystinuria without methylmalonic aciduria
hydrocephalus with stenosis of the aqueduct of sylvius
legionellosis
neonatal adrenoleukodystrophy
oral submucous fibrosis
pendred syndrome
phenylketonuria
pleomorphic liposarcoma
primary effusion lymphoma
primary hyperoxaluria type 1
proteus syndrome
pyruvate dehydrogenase deficiency
scrub typhus
systemic capillary leak syndrome
thoracic outlet syndrome
triple a syndrome
trochlear dysplasia
well-differentiated liposarcoma
werner syndrome
x-linked adrenoleukodystrophy
zellweger syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom